madman123
:
Will drop further, BNTX loosing market share. There are 170 vaccine trials ongoing in the world currently. And some are much better than BNTX with much better antibody response.
madman123
:
Only a matter of time before BNTX drop back to 200. Plus, the pandemic is not going to go on forever. Much of the developed world have been vaccinated.
Larry Edelweiss
madman123
:
Wrong. pandemic far from over with different variants popping up. They will only further benefit from the need for booster shots from the developed countries + the first mover advantage thanks to partnership with Pfizer in the race for full FDA approval. Hard to justify their 450$ ++ price but to say they are slowly losing out is just silly. There are tons of vaccines on trials but who can beat them in terms of brand recognition now that it's always amongst the first name that came to people's mind when talking about Covid vaccines. The truly overvalued stock is Moderna as their market cap is almost double that of BioNTech. Their seemingly similar stock price is just half of the picture.
Joachim8
:
This stock is solid. The U.S. will be shortly starting to approve booster shots together with final approval by the FDA. Most of the world has not been vaccinated and boosters will increase the demand.
GM 1
madman123
:
Delta Variant requires a different form of a more potent vaccine. Believe thE pHarmas still working on it. The one that gets it first will have Its shares
Jacque MJ W : I feel you
Pochong : Just sell la. You already feeling the stock something wrong liao you still holding on to it for what?
madman123 : Will drop further, BNTX loosing market share. There are 170 vaccine trials ongoing in the world currently. And some are much better than BNTX with much better antibody response.
Dyls : it will go back up soon
madman123 : Only a matter of time before BNTX drop back to 200. Plus, the pandemic is not going to go on forever. Much of the developed world have been vaccinated.
Larry Edelweiss madman123 : Wrong. pandemic far from over with different variants popping up. They will only further benefit from the need for booster shots from the developed countries + the first mover advantage thanks to partnership with Pfizer in the race for full FDA approval. Hard to justify their 450$ ++ price but to say they are slowly losing out is just silly. There are tons of vaccines on trials but who can beat them in terms of brand recognition now that it's always amongst the first name that came to people's mind when talking about Covid vaccines. The truly overvalued stock is Moderna as their market cap is almost double that of BioNTech. Their seemingly similar stock price is just half of the picture.
Joachim8 : This stock is solid. The U.S. will be shortly starting to approve booster shots together with final approval by the FDA. Most of the world has not been vaccinated and boosters will increase the demand.
GM 1 madman123 : Delta Variant requires a different form of a more potent vaccine. Believe thE pHarmas still working on it. The one that gets it first will have Its shares![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")